Ocugen announced positive 12-month data from its OCU410 Phase 2 trial showing significant reduction in lesion growth for geographic atrophy, supporting a Phase 3 trial planned for late 2026. The company completed enrollment for key trials in retinitis pigmentosa and Stargardt disease, aiming for Biologics License Application submissions by 2027. Ocugen also priced a $115 million convertible senior notes offering, expected to extend its cash runway into 2028 after retiring higher-interest debt. These developments position Ocugen for potential regulatory approvals and commercialization of its gene therapies targeting blindness diseases.
Dycom Industries reported a record first quarter with contract revenues up 56.1% to $1.965 billion and adjusted net income nearly doubling to $134.3 million. The company raised its full-year fiscal 2027 revenue outlook to $7.38-$7.65 billion, driven ...
BrewDog, part of Tilray Brands, is rolling out a major summer campaign across the UK tied to the global football tournament. The campaign features a "Win a Year of Beer" contest with special cans hidden in over 2.8 million packs at major retailers, p...
Atea Pharmaceuticals announced Phase 1 results indicating their Hepatitis C treatment regimen, combining bemnifosbuvir and ruzasvir, has a low risk of drug-drug interactions with common medications like omeprazole and rosuvastatin. This supports easi...
Girard Sharp LLP is investigating potential securities claims for former Discover investors who received Capital One shares after Capital One acquired Discover in May 2025. Since the merger, Capital One's stock price has declined, leading to possible...
Sunshine Silver, a mining and refining company based in Idaho, is preparing for a $2.32 billion initial public offering on the New York Stock Exchange. The company aims to raise up to $330 million by selling 20 million shares priced between $13.50 an...
